In addition to diabetes and obesity, GLP-1 drugs have been widely applied in clinical trials in various diseases, including fatty liver disease, cardiovascular disease, Alzheimer's disease, Parkinson's disease, and chronic kidney disease
Liraglutide, initiated at 0.6 mg per day, was escalated to the maximum tolerated dose or up to 3.0 mg per day over 4 weeks
Syvlahti, E., Rkklinen, V., Aaltonen, J., Lehtinen, V
Regarding blood pressure specifically , the modest reductions observed are generally beneficial
Some individuals may experience mild redness or slight discomfort at the injection site, but these effects are usually temporary
ng gi sn phm cn thn thch Nguyn Tun Anh mua ti rocy.vn c xp hng 5 5 sao Sn phm chnh hng, y tem mc